PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Pediatrics. Author manuscript; available in PMC 2017 August 7.
Published in final edited form as:
PMCID: PMC5545791
NIHMSID: NIHMS870913

Fatal Myocarditis Associated With HHV-6 Following Immunosuppression in Two Children

Abstract

Fatal myocarditis is a rare complication in immunosuppressed children. Recent reports have linked human herpesvirus 6 (HHV-6) infection, typically a benign infection in childhood, with myocarditis. HHV-6 can reactivate during periods of immunosuppression. Here, we report 2 cases in which children were immunosuppressed, one for treatment of Evans syndrome and the other post hematopoietic stem cell transplantation, who developed rapid and fatal HHV-6-associated myocarditis. These cases suggest that HHV-6 infection should be considered as an etiology of myocarditis in immunosuppressed patients regardless of correlating blood levels. Early treatment of HHV-6 in patients with myocarditis could improve morbidity and mortality.

Human herpesvirus 6 [HHV-6] antibodies are found in >90% of adults in the Western Hemisphere, with infection acquired by 3 years of age.1 Moreover, HHV-6 DNA detection in blood via polymerase chain reaction (PCR) (reactivation) can occur in nearly 50% of patients after hematopoietic cell transplantation (HCT).2 HHV-6 reactivation most commonly manifests as viremia within the first 28 days of HCT and can be associated with several complications, including encephalitis, altered mental status, bone marrow suppression, and delayed engraftment.25 HHV-6 treatment guidelines are most often practitioner-based.

Viral myocarditis can be seen in the immunocompromised setting and has etiologies including enterovirus, adenovirus, parvovirus B19, and HHV-6 implicated in multiple studies.6,7 The gold standard diagnostic study is endomyocardial biopsy; it typically shows a lymphocytic infiltrate into the cardiac tissue. Recently, PCR of blood DNA has been used in diagnosis, but there are no definitive levels of viral DNA to make an accurate diagnosis. In this report, we show HHV-6 as a cause of myocarditis in 2 immunosuppressed pediatric patients.

CASE 1

A 13-year-old boy presented with priapism and a white blood count of 649 000. He was diagnosed with pre–B cell acute lymphoblastic leukemia based on flow cytometry. He was treated for high-risk acute lymphoblastic leukemia, although at the end of induction still had presence of disease. He underwent a double umbilical cord blood transplant with conditioning consisting of fludarabine, cyclophosphamide, and total body irradiation with graft versus host disease (GvHD) prophylaxis consisting of Cyclosporin A and mycophenylate mofetil.

Peritransplant complications included fevers, mucositis, mild transaminitis, and positive blood culture. Neutrophil engraftment occurred on day +9 and the patient was discharged on day +22. He was readmitted to the hospital on day +25 for fever and a generalized erythroderma with maculopapular features on 75% of his body. At the time of admission, the patient reported nasal congestion and epiphora. He was started on broad-spectrum antibiotics. Viral studies were negative for cytomegalovirus, adenovirus, and respiratory syncytial virus; however he was positive for HHV-6 with 7600 copies per mL from his blood by PCR. A skin biopsy indicated nonspecific findings but could not exclude GvHD; intravenous methylprednisolone was started at 48 mg/m2 for Grade II acute GvHD. The fever began to improve within 48 hours. The rash slightly improved day 5 after initiation of steroids. An echocardiogram showed no evidence of thrombi and an ejection fraction of 60% (similar to the pre-HCT ejection fraction).

On day +34, he had new fevers and antibiotic coverage was broadened, as well developed a new oxygen requirement, persistent tachycardia, hypotension, and decreased urine output. Physical examination revealed fine rales at the right base consistent with an infiltration on chest radiograph. HHV-6 viremia increased to 146 200 copies per mL of blood; at that time ganciclovir was initiated. The following day he developed acute respiratory decompensation with hypoxia and was transferred to the PICU for endotracheal intubation and mechanical ventilation. A repeat echocardiogram revealed an ejection fraction of 24%. The patient received inotropic support with multiple agents and transitioned to oscillatory ventilation for support. On day +36, the patient acutely worsened, requiring initiation of cardiopulmonary resuscitation; the attempts were ultimately unsuccessful and the patient died.

On autopsy, the heart was not grossly abnormal, but did show a pericardial effusion. The lungs showed pulmonary edema and bilateral pleural effusion. The cardiac tissue showed a mild interstitial lymphocytic infiltrate without evidence of fibrosis or viral inclusions on histologic sections; however, HHV-6 PCR was positive from the left ventricle and left lung upper pulmonary lobe. HHV-6A was detected in cardiac tissue by immunofluorescence, implicating viral myocarditis as the cause of death (Fig 1A).

FIGURE 1
HHV-6-A detection in cardiac tissue in 2 cases (A and B, respectively). Immunofluorescence was performed with ant-HHV-6A gp82/105 antibody. Images captured by confocal microscopy at ×400 magnification and ×1000 magnification (inset). Prominent ...

CASE 2

A 2-year-old previously healthy girl was evaluated in her primary care physician’s office for a fever and rash. On physical examination, the patient was found to have multiple ecchymoses and petechiae on the lower extremities. The patient’s laboratories showed a white blood cell count of 2400 cells/μl, a neutrophil count of 300 cells/μL, lymphocytes of 1300 cells/μL, hemoglobin of 9.9 g/dL, and platelets of 7000/μL. She had normal electrolytes and a normal chest radiograph. The patient was admitted to the hospital for further workup and started on broad-spectrum antibiotics. On hospital day 2, her white blood cell count decreased to 400 cells/μL, hemoglobin 7.9 g/dL, and platelets were 0. Bone marrow biopsy showed marrow cellularity of 80% to 90% with trilineage hematopoiesis without evidence of malignancy or dysplastic changes and normal flow cytometry. The patient was diagnosed with Evans syndrome and started on prednisone 2 mg/kg per day divided twice a day.

The patient continued to have intermittent fevers throughout her hospital course. Blood cultures were negative as were viral PCRs for Epstein-Barr virus and cytomegalovirus. The patient’s hemoglobin stabilized but she continued to have profound thrombocytopenia. On hospital day 6 the patient had decreased urine output, change in mental status, and hypotension and went into shock. Despite cardiopulmonary resuscitation, the patient died. Ultimately, HHV-6 PCR of the blood revealed 64 600 copies/mL. Autopsy results indicated acute lymphocytic myocarditis consistent with viral infection in both the left and right ventricles, and HHV-6A detected the cardiac tissue by immunofluorescence (Fig 1B).

DISCUSSION

HHV-6 reactivation is a common complication of HCT. Although plasma HHV-6 DNA load dynamics are often indicative of associated disease severity, the virus is highly cell-associated and can become persistent in tissues even at low circulating levels of viremia. Several studies have demonstrated disease states attributable to HHV-6 infection in the heart, brain, and liver tissues in the absence of detectable plasma viremia.8,9 Furthermore, HHV-6 infection has been reported to cause fatal myocarditis at very low levels of viremia.914

Currently, there is no unified approach for routine monitoring or treatment of HHV-6 in the setting of HCT.1517 There is some evidence that rapid diagnosis and intervention in cases of HHV-6 myocarditis may prevent fatality in these patients. Hakacova et al18 described the successful treatment of antiviral-resistant HHV-6B myocarditis in a young child with the drug Artesunate, which has shown efficacy against HHV-6 in vitro. More often, foscarnet or ganciclovir is used when HHV-6 is accompanied by symptoms.19,20 However, no randomized controlled trials have been conducted to determine which agent is best suited to treat HHV-6.

Endomyocardial biopsy is considered the gold standard for the diagnosis of myocarditis. However, the sensitivity of endomyocardial biopsy is low and myocarditis is confirmed on biopsy in only 20% to 50% of pediatric patients in the United States.21 In these cases, viral PCR of the tissue is often performed but could be an incidental finding due to the combination of circulating blood cells present in the tissue and the exquisite sensitivity of PCR. Although viral myocarditis usually results in a lymphocytic infiltrate, the immune response in case 1 may have been limited by the patient’s lymphopenia, as well as by steroid administration.

We report 2 cases of HHV-6 reactivation associated with myocarditis in immunosuppressed patients with direct staining of HHV-6 in heart tissue. Commonly, HHV-6 testing is performed only if a suggestive syndrome is present. Furthermore, therapy is often only initiated if high-grade viremia is present. In both cases, our patients initially had low-grade viremia and developed fatal myocarditis. Treatment of myocarditis in the immunocompromised setting warrants further investigation and consideration of early therapy regardless of HHV-6 viral load in the blood. This could be critical in decreasing morbidity and mortality in these patients.

Acknowledgments

FUNDING: This work was supported in part by the NIH/NICHD K12 HD068322 (HES and TCL) and K08HL108998 (TCL) and the St Baldrick’s Foundation (HES and KAT). Funded by the National Institutes of Health (NIH).

ABBREVIATIONS

GvHD
graft versus host disease
HCT
hematopoietic cell transplantation
HHV-6
human herpesvirus 6
PCR
polymerase chain reaction

Footnotes

Dr Stefanski conceptualized and designed the study, and drafted the initial manuscript; Ms Thibert, Mr Pritchett, and Dr Prusty carried out the initial analyses, and reviewed and revised the manuscript; Drs Wagner and Lund oversaw the data and critically reviewed the manuscript; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

References

1. Stone RC, Micali GA, Schwartz RA. Roseola infantum and its causal human herpesviruses. Int J Dermatol. 2014;53(4):397–403. [PubMed]
2. Dulery R, Salleron J, Dewilde A, et al. Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. Biol Blood Marrow Transplant. 2012;18(7):1080–1089. [PubMed]
3. Gotoh M, Yoshizawa S, Katagiri S, et al. Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2–4 acute graft-versus-host disease. Transpl Infect Dis. 2014;16(3):440–449. [PubMed]
4. Hentrich M, Oruzio D, Jäger G, et al. Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. Br J Haematol. 2005;128(1):66–72. [PubMed]
5. Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40(7):932–940. [PubMed]
6. Rohayem J, Dinger J, Fischer R, Klingel K, Kandolf R, Rethwilm A. Fatal myocarditis associated with acute parvovirus B19 and human herpesvirus 6 coinfection. J Clin Microbiol. 2001;39(12):4585–4587. [PMC free article] [PubMed]
7. Kühl U, Lassner D, Wallaschek N, et al. Chromosomally integrated human herpesvirus 6 in heart failure: prevalence and treatment. Eur J Heart Fail. 2015;17(1):9–19. [PubMed]
8. Buyse S, Roque-Afonso AM, Vaghefi P, et al. Acute hepatitis with periportal confluent necrosis associated with human herpesvirus 6 infection in liver transplant patients. Am J Clin Pathol. 2013;140(3):403–409. [PubMed]
9. Leveque N, Boulagnon C, Brasselet C, et al. A fatal case of Human Herpesvirus 6 chronic myocarditis in an immunocompetent adult. J Clin Virol. 2011;52(2):142–145. [PubMed]
10. Andréoletti L, Lévêque N, Boulagnon C, Brasselet C, Fornes P. Viral causes of human myocarditis. Arch Cardiovasc Dis. 2009;102(6–7):559–568. [PubMed]
11. Ashrafpoor G, Andréoletti L, Bruneval P, et al. Fulminant human herpesvirus 6 myocarditis in an immunocompetent adult: role of cardiac magnetic resonance in a multidisciplinary approach. Circulation. 2013;128(23):e445–e447. [PubMed]
12. Kühl U, Pauschinger M, Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation. 2005;111(7):887–893. [PubMed]
13. Kühl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005;112(13):1965–1970. [PubMed]
14. Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006;114(15):1581–1590. [PubMed]
15. Betts BC, Young JA, Ustun C, Cao Q, Weisdorf DJ. Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary? Biol Blood Marrow Transplant. 2011;17(10):1562–1568. [PMC free article] [PubMed]
16. Sakai R, Kanamori H, Motohashi K, et al. Long-term outcome of human herpesvirus-6 encephalitis after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(9):1389–1394. [PubMed]
17. Scheurer ME, Pritchett JC, Amirian ES, Zemke NR, Lusso P, Ljungman P. HHV-6 encephalitis in umbilical cord blood transplantation: a systematic review and meta-analysis. Bone Marrow Transplant. 2013;48(4):574–580. [PubMed]
18. Hakacova N, Klingel K, Kandolf R, Engdahl E, Fogdell-Hahn A, Higgins T. First therapeutic use of Artesunate in treatment of human herpesvirus 6B myocarditis in a child. J Clin Virol. 2013;57(2):157–160. [PubMed]
19. Ishiyama K, Katagiri T, Ohata K, et al. Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation. Transpl Infect Dis. 2012;14(1):33–39. [PubMed]
20. Ishiyama K, Katagiri T, Hoshino T, Yoshida T, Yamaguchi M, Nakao S. Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT. Bone Marrow Transplant. 2011;46(6):863–869. [PubMed]
21. Daubeney PE, Nugent AW, Chondros P, et al. National Australian Childhood Cardiomyopathy Study. Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study. Circulation. 2006;114(24):2671–2678. [PubMed]